364 related articles for article (PubMed ID: 16083325)
41. Challenges in malaria control in sub-Saharan Africa: the vaccine perspective.
Lusingu JP; Von Seidlein L
Tanzan J Health Res; 2008 Oct; 10(4):253-66. PubMed ID: 19402588
[TBL] [Abstract][Full Text] [Related]
42. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
Bell BA; Wood JF; Bansal R; Ragab H; Cargo J; Washington MA; Wood CL; Ware LA; Ockenhouse CF; Yadava A
Vaccine; 2009 Feb; 27(9):1448-53. PubMed ID: 19138714
[TBL] [Abstract][Full Text] [Related]
43. Malaria vaccine: a current perspective.
Sharma S; Pathak S
J Vector Borne Dis; 2008 Mar; 45(1):1-20. PubMed ID: 18399312
[TBL] [Abstract][Full Text] [Related]
44. [Malaria: the vaccine enters a phase III trial].
Nau JY
Rev Med Suisse; 2008 Dec; 4(184):2760. PubMed ID: 19160644
[No Abstract] [Full Text] [Related]
45. Malaria: new vaccines for old?
Waters A
Cell; 2006 Feb; 124(4):689-93. PubMed ID: 16497579
[TBL] [Abstract][Full Text] [Related]
46. GlaxoSmithKline malaria vaccine phase 3 trial heralded.
Franz S
Nat Biotechnol; 2011 Dec; 29(12):1060-2. PubMed ID: 22158344
[No Abstract] [Full Text] [Related]
47. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
Patarroyo ME; Patarroyo MA
Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
[TBL] [Abstract][Full Text] [Related]
48. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
49. Policy challenges in malaria vaccine introduction.
Moree M; Ewart S
Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):248-52. PubMed ID: 15331844
[TBL] [Abstract][Full Text] [Related]
50. Initial lessons from public-private partnerships in drug and vaccine development.
Wheeler C; Berkley S
Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
[TBL] [Abstract][Full Text] [Related]
51. Initiating malaria control programs in the third world: directives for short- and long-term solutions.
Basu S
J Health Soc Policy; 2002; 15(1):59-75. PubMed ID: 12212933
[TBL] [Abstract][Full Text] [Related]
52. Advances in malaria genomics since MIM Arusha, 2002.
Carucci DJ
Acta Trop; 2005 Sep; 95(3):260-4. PubMed ID: 16018960
[TBL] [Abstract][Full Text] [Related]
53. Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
O'Meara WP; Lang T
Parasite Immunol; 2009 Sep; 31(9):574-81. PubMed ID: 19691560
[TBL] [Abstract][Full Text] [Related]
54. Adjuvants for malaria vaccines.
Coler RN; Carter D; Friede M; Reed SG
Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556
[TBL] [Abstract][Full Text] [Related]
55. Prospects for a malaria vaccine.
Coppel RL
Microbiol Sci; 1986 Oct; 3(10):292-5. PubMed ID: 3153563
[TBL] [Abstract][Full Text] [Related]
56. Towards a malaria vaccine for Papua New Guinea.
Reeder JC
P N G Med J; 2001; 44(1-2):17-23. PubMed ID: 12418674
[TBL] [Abstract][Full Text] [Related]
57. [Malaria.02: research for a world-wide exposition].
Genton B; D'Acremont V
Rev Med Suisse Romande; 2002 Oct; 122(10):479-84. PubMed ID: 12494779
[TBL] [Abstract][Full Text] [Related]
58. Protective human immunity as a vaccine discovery tool for falciparum malaria.
Nixon CP; Friedman JF; Knopf PM; Duffy PE; Kurtis JD
Transfusion; 2005 Aug; 45(2 Suppl):81S-87S. PubMed ID: 16086793
[TBL] [Abstract][Full Text] [Related]
59. Progress and challenges for malaria vaccines.
Richie TL; Saul A
Nature; 2002 Feb; 415(6872):694-701. PubMed ID: 11832958
[TBL] [Abstract][Full Text] [Related]
60. Malaria: the end of the beginning.
Maher B
Nature; 2008 Feb; 451(7182):1042-6. PubMed ID: 18305518
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
